date:Dec 10, 2012
million). This includes the impact of the resveratrol acquisition. Based on the current cash position and the above projections, Evolva expects to be financed through year-end 2013 without further financing.
In late August 2012, Evolva announced its plan to raise CHF 10 20 million in new equity. We, and our financial advisors, are in active discussions with potential investors regarding financing and expect to complete the transaction in the first quarter of 2013. We have received a non-bindi